Histone methyltransferase: Difference between revisions

Revision as of 12:40, 24 March 2016

Function

Histone methyltransferase (HMT) are histone-lysine N-methyltransferase (KHMT) and histone-arginine N-methyltransferase (RHMT) which catalyzes the transfer of methyl groups to lysine and arginine residues of histones^[1]. HMT use S-adenosyl methionine (SAM) or S-adenosyl homocysteine (SAH) as the methyl donor. KHMT can be SET domain-containing or non-SET domain-containing. The SET domain contains the catalytic core of KHMT and targets the lysine tail region of KHMT. CxxC domain is a zinc finger domain.

Relevance

Inhibitors of the histone-lysine N-methyltransferase SMYD2 which represses the tumor-suppressing activities of p53 are studied as cancer therapy drugs^[2].

Disease

Aberrant HMT plays a role in cancer, intellectual disability syndromes and regulation of tissue aging^[3].

Structural highlights

Human KHMT binds SAH in the peptide binding groove with the histone H3 peptide assuming an extended conformation and the methylated lysine inserted in a hydrophobic environment^[4].

Human histone-lysine N-methyltrasferase (grey, green) complex with methylated lysine histone H3 peptide (rust, aqua) and S-adenosyl homocysteine (SAH) (PDB entry 1o9s)

Drag the structure with the mouse to rotate

3D Structures of histone methyltransferase3D Structures of histone methyltransferase

Updated on 24-March-2016

DOT1L histone methyltransferase
- 1nw3 – hHMT DOT1L – human
Euchromatic histone methyltransferase
- 2igq – hHMT-1 C terminal
Histone-lysine N-methyltransferase
- 2j8a – KHMT SET1 RRM domain – yeast
- 3s8s – hKHMT SETD1A RRM domain
- 2mdc, 2mdj - hKHMT SETD2 WW domain - NMR
- 2mdi - hKHMT SETD2 WW domain (mutant) - NMR
- 2r3a – hKHMT Suv39H2
- 3rq4 - hKHMT Suv420H2
- 3s8p - hKHMT Suv420H1
- 3mts - hKHMT Suv39H1 chromo domain
- 1h3i - hKHMT SET7/9 residues 52-344
- 2o8j - hKHMT H3K9 residues 913-1193
- 2lv9 - hKHMT Mll5 residues 109-188 - NMR
- 2kyu - hKHMT Mll Phd3 finger – NMR
- 4gnd - hKHMT Nsd3 Phd5-C5HCH
- 4rxj - hKHMT Nsd3 residues 953-1064
- 4yz8 - hKHMT Nsd3 residues 1054-1285
- 3lqh - hKHMT Mll Phd bromodomain
- 3b7b - hKHMT ankyrin repeat domains 2-7
- 3bo5 – hKHMT Setmar methyltransferase domain
- 3k9j, 3k9k – hKHMT Setmar transposable domain (mutant)
- 3dlm - hKHMT Setmdb1 Tudor domain
- 3n71 - hKHMT Smyd1
- 3rsn, 3s32 – hKHMT Ash2 N terminal
- 3toj – hKHMT Ash2 Spry domain
- 4ijd – hKHMT Prdm9
- 4mi0 – hKHMT Ezh2
- 4mi5 – hKHMT Ezh2 SET domain
- 1ml9 – NcKHMT Dim-5 – Neurospora crassa
- 1n3j – PvKHMT – Paramecium bursaria chlorella virus
- 1u2z – yKHMT C terminal
- 2l7p – AtKHMT Ashh2 CW domain – Arabidopsis thaliana - NMR
- 2lxe – AtKHMT Suvr4 SET31 - NMR
Histone-lysine N-methyltransferase binary complexes
- 2kkf – hKHMT Hrx CxxC domain + DNA – NMR
- 4nw3 – hKHMT Mll CxxC domain + DNA
- 4pzi – hKHMT CxxC domain + DNA
- 3q0b, 3q0c, 3q0d, 3q0f – hKHMT SRA domain + DNA
- 3qow – hKHMT + SAM
- 4fmu – hKHMT SETD2 + inhibitor
- 4h12 – hKHMT SETD2 + SAH
- 3smt – hKHMT SETD3 + SAM
- 4bup, 3ooi – hKHMT SET domain + SAM
- 3qox, 3sx0 – hKHMT + SAH
- 3sr4, 3uwp, 4ek9, 4ekg, 4eki, 4eqz, 4er0, 4er3, 4er5, 4er6, 4er7, 4hra - hKHMT catalytic domain + inhibitor
- 2w5y – hKHMT Hrx methyltransferase domain + SAH
- 3f2k – hKHMT Setmar SET domain + LYFA peptide
- 3sw9, 3swc – hKHMT SET domain + peptide
- 4gne, 4gnf, 4gng - hKHMT Nsd3 Phd5-C5HCH + H3 peptide
- 3b95 - hKHMT ankyrin repeat domain + H3 peptide
- 3lqi, 3lqj - hKHMT Mll1 3rd Phd finger and bromodomain + H3 peptide
- 3rib – hKHMT Smyd2 + SAH
- 3s7j, 3tg4 - hKHMT Smyd2 + SAM
- 4wuy - hKHMT Smyd2 + inhibitor
- 1mt6 - hKHMT SET7/9 residues 58-337 + SAH
- 1n6a – hKHMT SET7/9 SET domain + SAM
- 1n6c – hKHMT SET7/9 residues 70-366 + SAM
- 3cbp - hKHMT SET7/9 SET domain + sinefungin
- 3vuz, 3vv0 - hKHMT SET7/9 SET domain + deoxyadenosine derivative
- 4l58 - hKHMT PHD-type zinc finger domain + H3 peptide
Histone-lysine N-methyltransferase ternary complex
- 2w5z – hKHMT Hrx methyltransferase domain + SAH + histone peptide
- 1o9s - hKHMT SET7/9 SET domain + SAH + H3 peptide
- 2bqz - hKHMT SET7 SET domain + SAH + H4 peptide
- 3f9w, 3f9x, 3f9y, 3f9z - hKHMT SETD8 SET domain + SAH + H4 peptide
- 4ij8 - hKHMT SETD8 + SAM + H3 peptide
- 4j7i, 4j83, 4j8o, 4j7f - hKHMT SETD7 + SAH + TFIID peptide
- 3fpd, 3k5k, 3mo0, 3mo2, 3mo5, 3rjw, 4nvq - hKHMT SET domain + SAH + inhibitor
- 2rfi, 3hna - hKHMT H3K9 catalytic domain + SAH + H3 peptide
- 1xqh - hKHMT SET7/9 SET domain + SAH + p53 peptide
- 2f69, 3m53 - hKHMT SET7/9 SZET domain + SAH + TAF10 peptide
- 3m54, 3m55, 3m56, 3m57, 3m58, 3m59, 3m5a - hKHMT SET7/9 SET domain (mutant) + SAH + TAF10 peptide
- 3cbm - hKHMT SET7/9 SET domain + SAM + estrogen receptor peptide
- 4e47, 4jds, 4jlg - hKHMT SET7/9 SET domain + SAM + inhibitor
- 3cbo - hKHMT SET7/9 SET domain + SAH + estrogen receptor peptide
- 3os5 - hKHMT SET7/9 SET domain + SAH + DNMT1 peptide
- 3qxy, 3rc0 - hKHMT SETD6 SET domain + p65 peptide + SAM
- 3s7b - hKHMT Smyd2 + SAM + inhibitor
- 3s7d, 3s7f, 3tg5 - hKHMT Smyd2 + SAH + p53 peptide
- 4o6f – hKHMT Smyd2 (mutant) + SAH + estrogen receptor peptide
- 1zkk - hKHMT + SAH + H4 peptide
- 4c1q - hKHMT SET domain + SAH + H3 peptide
- 4i51 - hKHMT (mutant) + SAH + H3 peptide
- 1peg - NcKHMT Dim-5 + SAH + H3 peptide
- 2g46 – PvKHMT + SAH + H3 peptide
- 4au7 - mKHMT + SAH + H4 peptide - mouse
Histone-arginine N-methyltransferase (Carm1)
- 2v74, 2v7e – mRHMT catalytic domain
- 4c03, 4c06, 4c07, 4c08 – mRHMT 6
- 4c04 – mRHMT 6 + inhibitor
- 4c05 – mRHMT 6 + SAH
- 4c4a – mRHMT 7 + SAH
- 2obq – rRHMT N terminal - rat
- 3b3g, 3b3j – rRHMT catalytic domain
- 3b3f – rRHMT catalytic domain + SAH
- 2y1w, 2y1x – hRHMT 4 catalytic domain + sinefungin + indole inhibitor
- 4ikp – hRHMT 4 catalytic domain + purine derivative
- 4gqb – hRHMT 5 + methylsome protein 50 + H4 peptide
- 4qqk – hRHMT 6
- 4hc4 – hRHMT 6 (mutant)
- 4qpp – hRHMT 6 (mutant) + peptide + inhibitor

ReferencesReferences

↑ Trievel RC. Structure and function of histone methyltransferases. Crit Rev Eukaryot Gene Expr. 2004;14(3):147-69. PMID:15248813
↑ Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, Cheung T, Garcia-Arenas R, Cowen S, Wu J, Godin R, Chen H, Keen N. Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure. 2011 Jul 20. PMID:21782458 doi:10.1016/j.str.2011.06.011
↑ Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012 Apr 3;13(5):343-57. doi: 10.1038/nrg3173. PMID:22473383 doi:http://dx.doi.org/10.1038/nrg3173
↑ Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003 Feb 6;421(6923):652-6. Epub 2003 Jan 22. PMID:12540855 doi:10.1038/nature01378

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman

[1] Trievel RC. Structure and function of histone methyltransferases. Crit Rev Eukaryot Gene Expr. 2004;14(3):147-69. PMID:15248813

[2] Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, Cheung T, Garcia-Arenas R, Cowen S, Wu J, Godin R, Chen H, Keen N. Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure. 2011 Jul 20. PMID:21782458 doi:10.1016/j.str.2011.06.011

[3] Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012 Apr 3;13(5):343-57. doi: 10.1038/nrg3173. PMID:22473383 doi:http://dx.doi.org/10.1038/nrg3173

[4] Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003 Feb 6;421(6923):652-6. Epub 2003 Jan 22. PMID:12540855 doi:10.1038/nature01378

[1]

[2]

[3]

[4]

@@ Line 5: / Line 5: @@
 == Relevance ==
-Inhibitors of the histone-lysine N-methyltransferase SMYD2 which represses the tumor-suppressing activities of p53 are studied as cancer therapy drug<ref>PMID:21782458</ref>.s.
+Inhibitors of the histone-lysine N-methyltransferase SMYD2 which represses the tumor-suppressing activities of p53 are studied as cancer therapy drugs<ref>PMID:21782458</ref>.
 == Disease ==
@@ Line 64: / Line 64: @@
 *Histone-lysine N-methyltransferase binary complexes
-**[[2kkf]] – hKHMT Hrx CxxC domain +_DNA – NMR<br />
+**[[2kkf]] – hKHMT Hrx CxxC domain + DNA – NMR<br />
 **[[4nw3]] – hKHMT Mll CxxC domain + DNA <br />
 **[[4pzi]] – hKHMT CxxC domain + DNA <br />
-**[[3q0b]], [[3q0c]], [[3q0d]], [[3q0f]] – hKHMT SRA domain +_DNA <br />
+**[[3q0b]], [[3q0c]], [[3q0d]], [[3q0f]] – hKHMT SRA domain + DNA <br />
 **[[3qow]] – hKHMT + SAM <br />
 **[[4fmu]] – hKHMT SETD2 + inhibitor <br />

Histone methyltransferase: Difference between revisions

Revision as of 12:40, 24 March 2016

Contents

Function

Relevance

Disease

Structural highlights

3D Structures of histone methyltransferase3D Structures of histone methyltransferase

ReferencesReferences

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Navigation menu

Histone methyltransferase: Difference between revisions

Revision as of 12:40, 24 March 2016

Function

Relevance

Disease

Structural highlights

3D Structures of histone methyltransferase3D Structures of histone methyltransferase

ReferencesReferences

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Navigation menu

Search